Revcovi

Active Ingredient(s): Elapegademase-lvlr
FDA Approved: * October 5, 2018
Pharm Company: * LEADIANT BIOSCI INC
Category: Genetic Disorders

Adenosine deaminase deficiency (ADA deficiency) is a metabolic disorder that causes immunodeficiency. It is caused by mutations in the ADA gene. It accounts for about 10–15% of all cases of autosomal recessive forms of severe combined immunodeficiency (SCID) among non-inbred populations.[1] ADA deficiency can present in infancy, childhood, adolescence, or adulthood. Age of onset and severity is related to some 29 known genotypes associated with the disorder.[2... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Revcovi 1.6 mg/ml Intramuscular Injection
NDC: 10122-502
Labeler:
Chiesi USA, Inc.
Revcovi 1.6 mg/ml Intramuscular Injection
NDC: 57665-002
Labeler:
Leadiant Biosciences, Inc.